$NLSP
NLS Pharmaceutics Ltd. Stock $nlsp

$nlsp Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000121390024043570 Filed on May 15, 2024

Income Statement

Concept	2023 Q4	2023	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.733M	$5.899M	$6.506M
YoY Change	-18.71%	-9.33%	9.5%
% of Gross Profit
Research & Development	$1.525M	$5.908M	$8.977M
YoY Change	-55.58%	-34.18%	51.65%
% of Gross Profit
Depreciation & Amortization	$5.710K	$11.41K	$11.41K
YoY Change	0.0%	0.0%	13.51%
% of Gross Profit
Operating Expenses	$4.258M	$11.81M	$15.48M
YoY Change	-37.34%	-23.74%	30.54%
Operating Profit		-$11.80M	-$15.48M
YoY Change		-23.78%	30.54%
Interest Expense	-$145.0K	$119.9K	-$90.82K
YoY Change	77.63%	-232.04%	6.28%
% of Operating Profit
Other Income/Expense, Net	-$156.7K	-$219.8K	$10.05K
YoY Change	177.82%	-2288.27%	-157.99%
Pretax Income	-$4.559M	-$12.17M	-$16.50M
YoY Change	-41.96%	-26.21%	38.08%
Income Tax
% Of Pretax Income
Net Earnings	-$4.559M	-$12.17M	-$16.50M
YoY Change	-41.96%	-26.21%	38.08%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.32	-$0.84
Diluted Earnings Per Share	-$0.12	-$0.32	-$0.84
COMMON SHARES
Basic Shares Outstanding	35.67M shares	38.18M shares	19.68M shares
Diluted Shares Outstanding		38.18M shares	19.68M shares

Balance Sheet

Concept	2023 Q4	2023	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$897.7K	$897.7K	$8.948M
YoY Change	-89.97%	-89.97%	64.76%
Cash & Equivalents	$900.0K	$897.7K	$8.948M
Short-Term Investments
Other Short-Term Assets	$890.3K	$890.3K	$256.8K
YoY Change	246.74%	246.74%	1.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.823M	$1.823M	$9.246M
YoY Change	-80.28%	-80.28%	61.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.694K	$6.690K	$18.10K
YoY Change	-63.02%	-63.04%	-38.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$16.89K	$16.89K	$12.14K
YoY Change	39.05%	39.13%	0.83%
Total Long-Term Assets	$23.58K	$23.58K	$30.24K
YoY Change	-22.04%	-22.02%	-27.22%
TOTAL ASSETS
Total Short-Term Assets	$1.823M	$1.823M	$9.246M
Total Long-Term Assets	$23.58K	$23.58K	$30.24K
Total Assets	$1.847M	$1.847M	$9.277M
YoY Change	-80.09%	-80.09%	60.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.634M	$4.634M	$2.373M
YoY Change	95.24%	95.24%	36.63%
Accrued Expenses	$1.652M	$1.652M	$986.4K
YoY Change	67.5%	67.5%	48.01%
Deferred Revenue
YoY Change
Short-Term Debt	$1.634M	$1.634M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.920M	$7.920M	$3.360M
YoY Change	135.72%	135.72%	39.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.761M	$2.761M	$2.636M
YoY Change	4.73%	4.73%	-6.48%
Total Long-Term Liabilities	$2.761M	$2.761M	$2.636M
YoY Change	4.73%	4.73%	-6.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.920M	$7.920M	$3.360M
Total Long-Term Liabilities	$2.761M	$2.761M	$2.636M
Total Liabilities	$10.68M	$10.68M	$5.996M
YoY Change	78.13%	78.13%	14.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$70.37M
YoY Change	20.91%
Common Stock	$733.4K
YoY Change	9.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$64.86K
YoY Change
Treasury Stock Shares
Shareholders Equity	-$8.834M	-$8.834M	$3.281M
YoY Change
Total Liabilities & Shareholders Equity	$1.847M	$1.847M	$9.277M
YoY Change	-80.09%	-80.09%	60.92%

Cashflow Statement

Concept	2023 Q4	2023	2022
OPERATING ACTIVITIES
Net Income	-$4.559M	-$12.17M	-$16.50M
YoY Change	-41.96%	-26.21%	38.08%
Depreciation, Depletion And Amortization	$5.710K	$11.41K	$11.41K
YoY Change	0.0%	0.0%	13.51%
Cash From Operating Activities	-$2.388M	-$9.684M	-$13.88M
YoY Change	-61.57%	-30.22%	-7.07%
INVESTING ACTIVITIES
Capital Expenditures	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$1.912M
YoY Change		-100.0%	-91.48%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.634M	$1.634M	$17.40M
YoY Change	-88.17%	-90.61%	-14.46%
NET CHANGE
Cash From Operating Activities	-2.388M	-$9.684M	-$13.88M
Cash From Investing Activities	0.000
Cash From Financing Activities	1.634M	$1.634M	$17.40M
Net Change In Cash	-754.2K	-$8.051M	$3.517M
YoY Change	-109.93%	-328.9%	-34.41%
FREE CASH FLOW
Cash From Operating Activities	-$2.388M	-$9.684M	-$13.88M
Capital Expenditures	$0.00
Free Cash Flow	-$2.388M	-$9.684M	-$13.88M
YoY Change	-61.57%	-30.22%	-6.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	The Circle 6
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	8058
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Zurich
CY2023	dei	Entity Address Country EntityAddressCountry	CH
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39957
CY2023	dei	Entity Registrant Name EntityRegistrantName	NLS PHARMACEUTICS LTD.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	V8
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35671780	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	1358
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers AG
CY2023	dei	Auditor Location AuditorLocation	Zurich, Switzerland
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	897680	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8948400	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	925382	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	297998	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1823062	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	9246398	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6694	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18102	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16885	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12143	usd
CY2023Q4	us-gaap	Assets Assets	1846641	usd
CY2022Q4	us-gaap	Assets Assets	9276643	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4633534	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2373276	usd
CY2023Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	1633746	usd
CY2022Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	0	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1652270	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	986437	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7919550	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3359713	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2499969	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2499969	usd
CY2023Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	260685	usd
CY2022Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	136122	usd
CY2023Q4	us-gaap	Liabilities Liabilities	10680204	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5995804	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35671780	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35671780	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32428893	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32428893	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	733413	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	668555	usd
CY2023Q4	nlsp	Treasury Shares Par Value TreasurySharesParValue	0.02
CY2023Q4	nlsp	Treasury Shares Par Value TreasurySharesParValue	0.02
CY2022Q4	nlsp	Treasury Shares Par Value TreasurySharesParValue	0.02
CY2022Q4	nlsp	Treasury Shares Par Value TreasurySharesParValue	0.02
CY2023Q4	nlsp	Treasury Shares Shares Issued TreasurySharesSharesIssued	3242887	shares
CY2023Q4	nlsp	Treasury Shares Shares Outstanding TreasurySharesSharesOutstanding	3242887	shares
CY2022Q4	nlsp	Treasury Shares Shares Issued TreasurySharesSharesIssued	0	shares
CY2022Q4	nlsp	Treasury Shares Shares Outstanding TreasurySharesSharesOutstanding	0	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	64858	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	61029437	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60864530	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70373484	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58201455	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-158071	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50791	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-8833563	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3280839	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1846641	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9276643	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5908288	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8976643	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5919452	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5898775	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6505721	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5941169	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	11807063	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	15482364	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	11860621	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-11807063	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-15482364	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-11860621	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-219812	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10045	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-17323	usd
CY2023	us-gaap	Interest Expense InterestExpense	119920	usd
CY2022	us-gaap	Interest Expense InterestExpense	95211	usd
CY2021	us-gaap	Interest Expense InterestExpense	48100	usd
CY2023	nlsp	Interest Expense Related Party1 InterestExpenseRelatedParty1	25233	usd
CY2022	nlsp	Interest Expense Related Party1 InterestExpenseRelatedParty1	5655	usd
CY2021	nlsp	Interest Expense Related Party1 InterestExpenseRelatedParty1	20034	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-922495	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-12172029	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16495680	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-11946078	usd
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	107280	usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-100948	usd
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	132358	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12279309	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16394732	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12078436	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38176020	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19682643	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11901636	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-8984057	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10054657	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	6742638	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13879371	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	50000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1149550	usd
CY2021	nlsp	Issuance Of Common Shares In Equity Transaction IssuanceOfCommonSharesInEquityTransaction	3548581	usd
CY2021	nlsp	Issuance Of Common Shares Partial Commitment Fee IssuanceOfCommonSharesPartialCommitmentFee	59455	usd
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	132358	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-11946078	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	542388	usd
CY2022	nlsp	Issuance Of Common Shares In Registered Direct Offering Net IssuanceOfCommonSharesInRegisteredDirectOfferingNet	1911513	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2047208	usd
CY2022	nlsp	Issuance Of Prefunded Warrants Net IssuanceOfPrefundedWarrantsNet	5348882	usd
CY2022	nlsp	Issuance Of Common Shares In At The Market Atm Financing IssuanceOfCommonSharesInAtTheMarketATMFinancing	30993	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	23692	usd
CY2022	nlsp	Issuance Of Common Shares In Private Placement Offerings Net IssuanceOfCommonSharesInPrivatePlacementOfferingsNet	7275549	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	2472616	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22730	usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-100948	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16495680	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3280839	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	164907	usd
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	107280	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-12172029	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-8833563	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-12172029	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16495680	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-11946078	usd
CY2023	us-gaap	Pension Expense PensionExpense	59526	usd
CY2022	us-gaap	Pension Expense PensionExpense	-34142	usd
CY2021	us-gaap	Pension Expense PensionExpense	47183	usd
CY2023	us-gaap	Depreciation Depreciation	11408	usd
CY2022	us-gaap	Depreciation Depreciation	11408	usd
CY2021	us-gaap	Depreciation Depreciation	10050	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	164906	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22730	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	77714	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	67008	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	41611	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-922495	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	632125	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-698116	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	188954	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	21804	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2260258	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	636263	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2269460	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	25605	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	20121	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-313342	usd
CY2023	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	640228	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	319989	usd
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-334045	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-42243	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-47679	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-38919	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9684466	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14936044	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	39560	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39560	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	11001569	usd
CY2022	nlsp	Proceeds From The Issuance Of Common Shares In Atm Financing ProceedsFromTheIssuanceOfCommonSharesInATMFinancing	30993	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1911513	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7275549	usd
CY2022	nlsp	Proceeds From The Issuance Of Prefunded Warrants Net ProceedsFromTheIssuanceOfPrefundedWarrantsNet	5348882	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1530000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	23692	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	704160	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1980200	usd
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	6742638	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1149550	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1633746	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	108610	usd
CY2021	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	277537	usd
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	150000	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	420020	usd
CY2021	nlsp	Payment On Convertible Loans Related Party PaymentOnConvertibleLoansRelatedParty	-111730	usd
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	670380	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	583443	usd
CY2021	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	3548582	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1633746	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17396669	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20337839	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-100	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-24744	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8050720	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3517198	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5337491	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8948400	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5431202	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93711	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	897680	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8948400	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5431202	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	145153	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	13248	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	339932	usd
CY2022	us-gaap	Notes Issued1 NotesIssued1	704160	usd
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	946912	usd
CY2021	nlsp	Issuance Of Common Shares To Consultant For Payment Of Expenses IssuanceOfCommonSharesToConsultantForPaymentOfExpenses	50000	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	59455	usd
CY2022	nlsp	Debt Discount On Convertible Loans DebtDiscountOnConvertibleLoans	67008	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Note 1</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Background:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (the “Company”) is an emerging biopharmaceutical company engaged in the discovery and development of life-improving drug therapies to treat rare and complex central nervous system disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as attention deficit hyperactivity disorder (“ADHD”). The Company’s lead product candidates are Quilience, to treat narcolepsy (type 1 and type 2), and Nolazol, to treat ADHD.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 2, 2021, the Company completed the closing of its initial public offering (the “Initial Public Offering”) of 4,819,277 units at a price of $4.15 per unit. Each unit consisted of one common share and one warrant to purchase one common share (the “Warrants”). The common shares and Warrants were immediately separable from the units and were issued separately. The common shares and Warrants began trading on the Nasdaq Capital Market on January 29, 2021 under the symbols “NLSP” and “NLSPW,” respectively. The Company received net proceeds of $17 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The Warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $4.15 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 722,891 common shares and/or Warrants to purchase 722,891 common shares at the public offering price of $0.01 per Warrant, of which the underwriters exercised its option to purchase Warrants to purchase up to 722,891 common shares. These Warrants were issued in the Company’s Initial Public Offering and therefore have the same exercise price of $4.15 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Company had an accumulated deficit of approximately $70.4 million and the Company incurred an operating loss for the year ended December 31, 2023, of approximately $11.8 million. To date, the Company has dedicated most of its financial resources to achieve and maintain Phase 3 readiness, research and development, clinical studies associated with its ongoing biopharmaceutical business and general and administrative expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Company’s cash and cash equivalents were $0.9 million. The Company’s existing cash and cash equivalents and access to existing financing arrangements will not be sufficient to fund operations for a period of one year from the issuance of these financial statements. The Company expects to continue to generate operating losses and negative operating cash flows for the next few years and will need additional funding to support its planned operating activities through profitability. The Company is actively exploring a range of options to raise funds, including strategic partnerships, out-licensing, or divestment of assets of the Company, and other future strategic actions. The Company is engaged in discussions with third party creditors to extend payment terms and has secured extensions on maturity dates on its existing bridge loans to December 31, 2024 and June 30, 2025 respectively (see subsequent event note). The future viability of the Company is dependent on its ability to extend payment terms with third party creditors until additional funds have been raised. There can be no assurance that such capital will be available within a sufficient period of time, in sufficient amounts or on terms acceptable to the Company. These conditions raise substantial doubt about the Company’s ability to continue as a going concern beyond one year from the issuance of these financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, the accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate continuation of the Company as a going concern for a period within one year from the issuance of these financial statements and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in these financial statements do not necessarily purport to represent realizable or settlement values. These financial statements do not include any adjustment that might result from the outcome of this uncertainty.</p>
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-11800000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	900000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As part of these financial statements, the Company’s significant estimates include the valuation allowance related to the Company’s deferred tax assets.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk include cash. At December 31, 2023 and 2022, substantially all of the cash balances are deposited in one banking institution. At various times, the Company has deposits in financial institutions which are in excess of federally insured limits.</p>
CY2023	nlsp	Tax Benefits More Likely To Be Recognized Percentage TaxBenefitsMoreLikelyToBeRecognizedPercentage	0.50	pure
CY2023Q4	nlsp	Vendor Prepayments VendorPrepayments	821266	usd
CY2022Q4	nlsp	Vendor Prepayments VendorPrepayments	65739	usd
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	24433	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	41243	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	10664	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	69019	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	36496	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	154520	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	925382	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	297998	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	39560	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	39560	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32866	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21458	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6694	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18102	usd
CY2023	us-gaap	Depreciation Depreciation	11408	usd
CY2022	us-gaap	Depreciation Depreciation	11408	usd
CY2023Q4	us-gaap	Unsecured Debt UnsecuredDebt	875000	chf
CY2023Q4	us-gaap	Unsecured Debt UnsecuredDebt	1000000	usd
CY2023Q3	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	500000	chf
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	332690	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	285398	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	112635	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	13000	usd
CY2022Q4	nlsp	Due To Related Party Expenses DueToRelatedPartyExpenses	4107	usd
CY2023Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	25605	usd
CY2023Q4	nlsp	Accrued Commitment Fee AccruedCommitmentFee	184672	usd
CY2022Q4	nlsp	Accrued Commitment Fee AccruedCommitmentFee	149496	usd
CY2023Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	960025	usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	510678	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	36643	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	23758	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1652270	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	986437	usd
CY2023	nlsp	Nonrefundable Upfront Payment NonrefundableUpfrontPayment	2500000	usd
CY2023	nlsp	Receive Nonrefundable Milestone Payments ReceiveNonrefundableMilestonePayments	16000000	usd
CY2023	nlsp	Estimated Total Transaction Price EstimatedTotalTransactionPrice	2500000	usd
CY2023	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	2500000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	2500000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	2500000	usd
CY2023	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	53920	usd
CY2022	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	39667	usd
CY2021	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	25206	usd
CY2023	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	14416	usd
CY2022	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	2743	usd
CY2021	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	2992	usd
CY2023	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	14767	usd
CY2022	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	12196	usd
CY2021	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	4249	usd
CY2022	us-gaap	Defined Benefit Plan Benefit Obligation Payment For Settlement DefinedBenefitPlanBenefitObligationPaymentForSettlement	72600	usd
CY2021	us-gaap	Defined Benefit Plan Benefit Obligation Payment For Settlement DefinedBenefitPlanBenefitObligationPaymentForSettlement	5810	usd
CY2022	us-gaap	Defined Benefit Plan Actuarial Gain Loss Immediate Recognition As Component In Net Periodic Benefit Cost Credit DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit	-3091	usd
CY2023	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Before Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax	-3031	usd
CY2022	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Before Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax	-2855	usd
CY2023	us-gaap	Defined Benefit Plan Other Costs DefinedBenefitPlanOtherCosts	2926	usd
CY2022	us-gaap	Defined Benefit Plan Other Costs DefinedBenefitPlanOtherCosts	2298	usd
CY2021	us-gaap	Defined Benefit Plan Other Costs DefinedBenefitPlanOtherCosts	1946	usd
CY2023	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	59525	usd
CY2022	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	-34142	usd
CY2021	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	20085	usd
CY2022Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	584737	usd
CY2021Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	927369	usd
CY2023	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	53920	usd
CY2022	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	39667	usd
CY2023	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	14416	usd
CY2022	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	2743	usd
CY2023	us-gaap	Defined Benefit Plan Other Changes DefinedBenefitPlanOtherChanges	38654	usd
CY2022	us-gaap	Defined Benefit Plan Other Changes DefinedBenefitPlanOtherChanges	-209035	usd
CY2023	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	-123388	usd
CY2022	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	152048	usd
CY2023	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	6087	usd
CY2022	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	23959	usd
CY2023Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	809028	usd
CY2022Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	584737	usd
CY2022Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	448615	usd
CY2021Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	608478	usd
CY2023	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	27844	usd
CY2022	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	-51764	usd
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	38737	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	37468	usd
CY2023	us-gaap	Defined Benefit Plan Plan Assets Contributions By Plan Participant DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant	20655	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Contributions By Plan Participant DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant	20608	usd
CY2023	us-gaap	Defined Benefit Plan Assets Transferred To From Plan DefinedBenefitPlanAssetsTransferredToFromPlan	17999	usd
CY2022	us-gaap	Defined Benefit Plan Assets Transferred To From Plan DefinedBenefitPlanAssetsTransferredToFromPlan	-150129	usd
CY2023	us-gaap	Defined Benefit Plan Administration Expenses DefinedBenefitPlanAdministrationExpenses	2926	usd
CY2022	us-gaap	Defined Benefit Plan Administration Expenses DefinedBenefitPlanAdministrationExpenses	2299	usd
CY2023	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	-2581	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	-13747	usd
CY2023Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	548343	usd
CY2022Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	448615	usd
CY2023Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	260685	usd
CY2022Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	136122	usd
CY2023Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	260685	usd
CY2022Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	136122	usd
CY2023Q4	nlsp	Projected Benefit Obligations Percentage Rate ProjectedBenefitObligationsPercentageRate	0.10	pure
CY2023	us-gaap	Defined Benefit Plan Amortization Of Transition Asset Obligation DefinedBenefitPlanAmortizationOfTransitionAssetObligation	0	usd
CY2022	us-gaap	Defined Benefit Plan Amortization Of Transition Asset Obligation DefinedBenefitPlanAmortizationOfTransitionAssetObligation	0	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-158073	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-50791	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-50791	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-151739	usd
CY2023	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	110313	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-88088	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plan Net Prior Service Costs Credit Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax	-3091	usd
CY2022	us-gaap	Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax	-6913	usd
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	161104	usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	53647	usd
CY2023	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax	3031	usd
CY2022	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax	2856	usd
CY2023	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-3031	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-2856	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-158073	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-50791	usd
CY2023Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0145	pure
CY2022Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0225	pure
CY2023Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0065	pure
CY2022Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0025	pure
CY2023Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Weighted Average Interest Crediting Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate	0.0145	pure
CY2022Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Weighted Average Interest Crediting Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate	0.0225	pure
CY2023Q4	nlsp	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedLongTermReturnOnAssets	0.023	pure
CY2022Q4	nlsp	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedLongTermReturnOnAssets	0.0295	pure
CY2023Q4	nlsp	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Inflation Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInflationRate	0.0125	pure
CY2022Q4	nlsp	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Inflation Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInflationRate	0.0085	pure
CY2023Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	809028	usd
CY2022Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	584737	usd
CY2023	nlsp	License Consideration LicenseConsideration	250000	usd
CY2023	nlsp	Milestone Payments Due Description MilestonePaymentsDueDescription	(i) $750,000 payable following the end of a Phase II meeting with the FDA, with the amount to be reduced to $375,000 if toxicology studies must be repeated; (ii) $2 million following the earlier of U.S. Food and Drug Administration (“FDA”) marketing authorization of Quilience or Nolazol; (iii) 1% of any upfront and milestone payments, if any, from any sublicensees and (iv) $3 million as a one-time payment upon the Company’s product candidate reaching $250 million in cumulative sales.
CY2023Q2	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	793112.46	usd
CY2023Q4	us-gaap	Litigation Reserve LitigationReserve	1007700.5	usd
CY2023	nlsp	Cash Placement CashPlacement	140000	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3015384	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.04
CY2023	nlsp	Sales Agreement Description SalesAgreementDescription	the Company entered into the Sales Agreement with Virtu, as sales agent. On April 13, 2022, the Company reduced the amount that may be sold pursuant to the Sales Agreement to $230,000. The Company will pay Virtu a commission rate of up to 3.0% of the gross proceeds from each sale of common shares and has agreed to provide Virtu with customary indemnification and contribution rights. The Company will also reimburse Virtu for certain specified expenses in connection with entering into the Sales Agreement. Under the Sales Agreement, common shares will be offered and sold pursuant to the Company’s shelf registration statement on Form F-3 (File No. 333-262489), declared effective by the Securities and Exchange Commission on February 11, 2023. In addition, under the Sales Agreement, sales of common shares may be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. The Company has no obligation to sell any of the common shares under the Sales Agreement and may at any time suspend the offering of its common shares upon notice and subject to other conditions
CY2023	nlsp	Commission Rate Percentage CommissionRatePercentage	0.03	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	19045043	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	19045043	shares
CY2023	nlsp	Common Share Warrants CommonShareWarrants	3304492	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	3242887	shares
CY2021Q4	nlsp	Diluted Shares Percentage DilutedSharesPercentage	0.15	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1333123	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.23
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	776344	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.76
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	245809	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.99
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1863658	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.07
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	449515	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1414143	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y9M18D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1283123	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.25
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	776344	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.51
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	399515	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.24
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	245809	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0.27
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1414146	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.39
CY2023Q4	us-gaap	Share Price SharePrice	0.59
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	54899	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	164906	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	471347	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M14D
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4337728	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3485243	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	264997	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	264997	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4602725	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3750239	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	852486	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1004681	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1119614	usd
CY2023	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	852486	usd
CY2022	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	1004681	usd
CY2021	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	1119614	usd
CY2023	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-852486	usd
CY2022	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-1004681	usd
CY2021	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-1119614	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.106	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.106	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.106	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.036	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.048	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.036	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.07	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.058	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.07	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	9700000	usd
CY2022	us-gaap	Salaries And Wages SalariesAndWages	12500	usd
CY2022Q4	nlsp	Consulting Agreement Hourly Rate ConsultingAgreementHourlyRate	270	usd
CY2023	nlsp	Addendums To Short Term Loan Agreements AddendumsToShortTermLoanAgreements	the Company entered into two addendums to the Short Term Loan Agreements with Ronald Hafner, the Company’s Chairman of the Board of Directors. These addendums extend the maturity date under the Loan Agreements to June 30, 2025, for the aggregate amount of CHF 750,000.
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.84
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.00
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11901636	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19682643	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38176020	shares
CY2021	nlsp	Capital Increase For Financing Transactions CapitalIncreaseForFinancingTransactions		usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense		usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023	nlsp	Proceeds From The Issuance Of Common Shares In Atm Financing ProceedsFromTheIssuanceOfCommonSharesInATMFinancing		usd
CY2021	nlsp	Proceeds From The Issuance Of Common Shares In Atm Financing ProceedsFromTheIssuanceOfCommonSharesInATMFinancing		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2023	nlsp	Proceeds From The Issuance Of Prefunded Warrants Net ProceedsFromTheIssuanceOfPrefundedWarrantsNet		usd
CY2021	nlsp	Proceeds From The Issuance Of Prefunded Warrants Net ProceedsFromTheIssuanceOfPrefundedWarrantsNet		usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2023	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt		usd
CY2022	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt		usd
CY2023	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2023	nlsp	Payment On Convertible Loans Related Party PaymentOnConvertibleLoansRelatedParty		usd
CY2022	nlsp	Payment On Convertible Loans Related Party PaymentOnConvertibleLoansRelatedParty		usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2023	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
CY2021	us-gaap	Notes Issued1 NotesIssued1		usd
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction		usd
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction		usd
CY2023	nlsp	Issuance Of Common Shares To Consultant For Payment Of Expenses IssuanceOfCommonSharesToConsultantForPaymentOfExpenses		usd
CY2022	nlsp	Issuance Of Common Shares To Consultant For Payment Of Expenses IssuanceOfCommonSharesToConsultantForPaymentOfExpenses		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	nlsp	Debt Discount On Convertible Loans DebtDiscountOnConvertibleLoans		usd
CY2021	nlsp	Debt Discount On Convertible Loans DebtDiscountOnConvertibleLoans		usd
CY2023	nlsp	Debt Discount On Convertible Loan Related Party DebtDiscountOnConvertibleLoanRelatedParty		usd
CY2022	nlsp	Debt Discount On Convertible Loan Related Party DebtDiscountOnConvertibleLoanRelatedParty		usd
CY2021	nlsp	Debt Discount On Convertible Loan Related Party DebtDiscountOnConvertibleLoanRelatedParty		usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables		usd
CY2023Q4	nlsp	Due To Related Party Expenses DueToRelatedPartyExpenses		usd
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable		usd
CY2023	us-gaap	Defined Benefit Plan Benefit Obligation Payment For Settlement DefinedBenefitPlanBenefitObligationPaymentForSettlement		usd
CY2023	us-gaap	Defined Benefit Plan Actuarial Gain Loss Immediate Recognition As Component In Net Periodic Benefit Cost Credit DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit		usd
CY2021	us-gaap	Defined Benefit Plan Actuarial Gain Loss Immediate Recognition As Component In Net Periodic Benefit Cost Credit DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit		usd
CY2021	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Before Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax		usd
CY2023	us-gaap	Other Comprehensive Income Defined Benefit Plan Net Prior Service Costs Credit Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax		usd
CY2023	us-gaap	Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax		usd
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax		usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax		usd
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax		usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax		usd
CY2023	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost Credit Excluding Service Cost Statement Of Income Or Comprehensive Income Extensible List DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2023#PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	49272323	usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001783036

Files In Submission

Name	View Source	Status
0001213900-24-043570-index-headers.html	Edgar Link	pending
0001213900-24-043570-index.html	Edgar Link	pending
0001213900-24-043570.txt	Edgar Link	pending
0001213900-24-043570-xbrl.zip	Edgar Link	pending
ea0205871-20f_nlspharma.htm	Edgar Link	pending
ea020587101ex12-1_nlspharma.htm	Edgar Link	pending
ea020587101ex12-2_nlspharma.htm	Edgar Link	pending
ea020587101ex13-1_nlspharma.htm	Edgar Link	pending
ea020587101ex13-2_nlspharma.htm	Edgar Link	pending
ea020587101ex15-1_nlspharma.htm	Edgar Link	pending
ea020587101ex16-1_nlspharma.htm	Edgar Link	pending
ea020587101ex2-1_nlspharma.htm	Edgar Link	pending
ea020587101ex4-17_nlspharma.htm	Edgar Link	pending
ea020587101ex4-18_nlspharma.htm	Edgar Link	pending
ea020587101ex97-1_nlspharma.htm	Edgar Link	pending
ex16-1_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
ea0205871-20f_nlspharma_htm.xml	Edgar Link	completed
image_018.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nlsp-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
nlsp-20231231_def.xml	Edgar Link	unprocessable
nlsp-20231231_pre.xml	Edgar Link	unprocessable
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nlsp-20231231_cal.xml	Edgar Link	unprocessable
nlsp-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NLSP
NLS Pharmaceutics Ltd. Stock $nlsp

2023 Q4 Form 20-F Financial Statement

#000121390024043570 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NLSP NLS Pharmaceutics Ltd. Stock $nlsp

2023 Q4 Form 20-F Financial Statement

#000121390024043570 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NLSP
NLS Pharmaceutics Ltd. Stock $nlsp